# Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

> **NCT03812562** · EARLY_PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 2 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **RADIATION:** Yttrium Y 90 Glass Microspheres

## Key facts

- **NCT ID:** NCT03812562
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-07
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03812562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03812562, "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03812562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*